PedAM
Pediatric Disease Annotations & Medicines
| tendinopathy | ||||
| Disease ID | 1926 |
|---|---|
| Disease | tendinopathy |
| Definition | Clinical syndrome describing overuse tendon injuries characterized by a combination of PAIN, diffuse or localized swelling, and impaired performance. |
| Synonym | tendinopathies tendinopathy [disease/finding] tendonopathies tendonopathy |
| UMLS | C1568272 |
| MeSH | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:11) C0020456 | hyperglycemia | 1 C0039520 | tenosynovitis | 1 C0242490 | enthesopathy | 1 C0011849 | diabetes mellitus | 1 C0029408 | osteoarthritis | 1 C0011847 | diabetes | 1 C0026760 | multiple epiphyseal dysplasia | 1 C0948265 | metabolic syndrome | 1 C0242992 | multiple chemical sensitivity | 1 C0020538 | hypertension | 1 C0410538 | pseudoachondroplasia | 1 |
| Curated Gene | (Waiting for update.) |
| Inferring Gene | (Waiting for update.) |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 1926 |
|---|---|
| Disease | tendinopathy |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:11) HP:0012531 | Pain | 20 HP:0030834 | Shoulder pain | 7 HP:0000969 | Dropsy | 2 HP:0030839 | Knee pain | 1 HP:0002758 | Osteoarthritis | 1 HP:0000819 | Diabetes mellitus | 1 HP:0012532 | Chronic pain | 1 HP:0002654 | Multiple epiphyseal dysplasia | 1 HP:0030883 | Femoroacetabular Impingement | 1 HP:0003074 | High blood glucose | 1 HP:0000822 | Hypertension | 1 |
| Disease ID | 1926 |
|---|---|
| Disease | tendinopathy |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:1) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:17) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1045485 | 22588838 | 342977 | NANOS3 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | CASP8 | 2 | 201284866 | G | C |
| rs1045485 | 22588838 | 841 | CASP8 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | CASP8 | 2 | 201284866 | G | C |
| rs1045485 | 22588838 | 4843 | NOS2 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | CASP8 | 2 | 201284866 | G | C |
| rs12722 | 19042922 | 1289 | COL5A1 | umls:C1568272 | BeFree | Furthermore, the MMP3 gene variant rs679620 and the COL5A1 marker rs12722 interact to modify the risk of tendinopathy. | 0.003181358 | 2009 | COL5A1;LOC101448202 | 9 | 134842570 | C | T |
| rs12722 | 19042922 | 4314 | MMP3 | umls:C1568272 | BeFree | Furthermore, the MMP3 gene variant rs679620 and the COL5A1 marker rs12722 interact to modify the risk of tendinopathy. | 0.000542884 | 2009 | COL5A1;LOC101448202 | 9 | 134842570 | C | T |
| rs1799983 | 22588838 | 342977 | NANOS3 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | NOS3 | 7 | 150999023 | T | G |
| rs1799983 | 22588838 | 4843 | NOS2 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | NOS3 | 7 | 150999023 | T | G |
| rs1799983 | 22588838 | 841 | CASP8 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | NOS3 | 7 | 150999023 | T | G |
| rs2779249 | 22588838 | 841 | CASP8 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | NOS2 | 17 | 27801555 | C | A |
| rs2779249 | 22588838 | 4843 | NOS2 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | NOS2 | 17 | 27801555 | C | A |
| rs2779249 | 22588838 | 342977 | NANOS3 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | NOS2 | 17 | 27801555 | C | A |
| rs384129 | 22588838 | 841 | CASP8 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | GAS2 | 11 | 22670928 | T | A |
| rs384129 | 22588838 | 342977 | NANOS3 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | GAS2 | 11 | 22670928 | T | A |
| rs384129 | 22588838 | 4843 | NOS2 | umls:C1568272 | BeFree | A total of 358 unaffected control (CON) participants [159 South Africa (SA CON) and 199 Australia (AUS CON)] and 166 affected AT (TEN) participants (87 SA TEN and 79 AUS TEN) were genotyped for four variants [CASP8 (rs384129), CASP8 (rs1045485), NOS3 (rs1799983), and NOS2 (rs2779249)]. | 0.000271442 | 2012 | GAS2 | 11 | 22670928 | T | A |
| rs679620 | 19042922 | 1289 | COL5A1 | umls:C1568272 | BeFree | Furthermore, the MMP3 gene variant rs679620 and the COL5A1 marker rs12722 interact to modify the risk of tendinopathy. | 0.003181358 | 2009 | MMP3 | 11 | 102842889 | T | C |
| rs679620 | 19042922 | 4314 | MMP3 | umls:C1568272 | BeFree | Furthermore, the MMP3 gene variant rs679620 and the COL5A1 marker rs12722 interact to modify the risk of tendinopathy. | 0.000542884 | 2009 | MMP3 | 11 | 102842889 | T | C |
| rs900379 | 24661680 | 2255 | FGF10 | umls:C1568272 | BeFree | The FGF3 TGGTA haplotype showed a tendency of association with tendinopathy (p=0.05), and so did FGF10 rs900379. | 0.000271442 | 2014 | FGF10 | 5 | 44369554 | C | T |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:4) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C1568272 | celecoxib | D000068579 | - | tendinopathy | MESH:D052256 | therapeutic | 11476468 | ||
| C1568272 | ciprofloxacin | D002939 | 85721-33-1 | tendinopathy | MESH:D052256 | marker/mechanism | 12869605 | ||
| C1568272 | indomethacin | D007213 | 53-86-1 | tendinopathy | MESH:D052256 | therapeutic | 1864449 | ||
| C1568272 | ofloxacin | D015242 | 82419-36-1 | tendinopathy | MESH:D052256 | marker/mechanism | 12120977 | ||
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D052256 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D052256 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
| MESH:D052256 | celebrex | celecoxib | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D052256 | celebrex | celecoxib | 100MG | CAPSULE;ORAL | Prescription | None | No | No |
FDA labeling changes(Total Drugs:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D052256 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D052256 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D052256 | 12/15/2006 | celebrex | celecoxib | Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) | New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs | Labeling | B | - | - | - | Pfizer | 08/23/2006 | FALSE' |
| MESH:D052256 | 12/15/2006 | celebrex | celecoxib | Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) | New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs | Labeling | B | - | - | - | Pfizer | 08/23/2006 | FALSE' |